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Over the last decades polyetiological metabolic diseases such as obesity and type 2 diabetes have
emerged as a global epidemic. Efficient strategies for prevention and treatment include dietary
intervention and the development of validated nutraceuticals. Safe extracts of edible plants
provide a resource of structurally diverse molecules that can effectively interfere with multi-
factorial diseases. In this study, we describe the application of ethanolic lemon balm (Melissa
officinalis) leaves extract for the treatment of insulin-resistance and dyslipidemia in mice. We
show that lemon balm extract (LBE) activates the peroxisome proliferator-activated receptors
(PPARs), which have key roles in the regulation of whole body glucose and lipid metabolism.
Application of LBE (0.6 mg/mL) to human primary adipocytes resulted in specific peroxisome
proliferator-activated receptor target gene expression. LBE treatment of insulin-resistant high-
fat diet-fed C57BL/6 mice (200 mg/kg/day) for 6 weeks considerably reduced hyperglycemia
and insulin resistance, plasma triacylglycerol, nonesterified fatty acids and LDL/VLDL choles-
terol levels. Taken together, ethanolic lemon balm extract can potentially be used to prevent
or concomitantly treat type 2 diabetes and associated disorders such as dyslipidemia and
hypercholesterolemia.
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Metabolic diseases such as type II diabetes are the result of life
style changes over the last decades [1], which require tailored
approaches for more efficient intervention. A key component
of such endeavours consists of the development of dietary in-
terventions including complementation with functional food
or nutraceuticals to combat metabolic disorders.
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Peroxisome proliferator-activated receptors (PPARs) be-
long to the class of nuclear receptors and regulate transcrip-
tional activity that can be modulated by binding of a large
variety of small ligands such as fatty acids [2]. These nuclear
receptors play crucial roles as molecular sensors of environ-
mental factors including nutritional constituents to finetune
glucose and lipid homeostasis, and are also important for
other physiological processes [2]. Three subtypes of PPARs
have been described, namely PPAR-, PPAR-/, and PPAR-
, which are expressed inmany cell types, includingmetabolic
target cells such as adipocytes [3]. Depending on the context,
the PPARs can (in part) complement the various actions of
each other. Specific activation of PPAR- or PPAR-/ by
small molecules counteracts various metabolic diseases in-
cluding dyslipidemia [4]. Synthetic agonists of PPAR- such
as the thiazolidinediones are efficient antidiabetic molecules
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
904 C. Weidner et al. Mol. Nutr. Food Res. 2014, 58, 903–907
Figure 1. In vitro and cell culture studies with lemon balm extract. (A–C) Binding to PPAR, PPAR/ and PPAR by natural-products
contained in lemon balm extract (LBE, g/ml) or reference ligands (nM). Binding of compounds was measured in a competitive time-
resolved fluorescence resonance energy transfer assay. Data are expressed as mean ± SD (n = 3). (D) Gene expression profile of lemon
balm extract (LBE) and rosiglitazone (RGZ) in human adipocytes. Primary adipocytes were treated with either 10 M RGZ, 0.6 mg/ml LBE
or vehicle only for 24 h and gene expression was analyzed with qPCR. (E) Human primary adipocytes were transfected with siRNA against
PPAR, PPAR/ and PPAR (checked bars) or control siRNA (solid bars) and were treated with either 300 M of the PPAR pan-agonist
bezafibrate (BFB), 0.2 mg/ml LBE or vehicle only for 24 h. Data are expressed as mean ± SEM (n = 3-4/group). *p ≤ 0.05; **p ≤ 0.01; ***p
≤ 0.001, vs. vehicle.
but showed a number of unwanted side effects including
weight gain, hepatotoxicity, edema, heart failure, osteoporo-
sis, and cancer [5]. Activation of all three PPAR subtypes
by pan-agonists has been proposed to combine the antihy-
perglycemic and insulin-sensitising effects of PPAR- ago-
nism with the beneficial properties of PPAR- agonism, that
is, the lowering of triacylglycerols and the increase of high-
density lipoprotein cholesterol levels [6]. But unfortunately,
many of these synthetic molecules including the dual PPAR-
/-activating glitazares were associated with adverse side
effects [7].
In general, the number of approved new chemical entities
has been declining for the past decade. Consequently, the
dominant single-component/single-target concept of phar-
maceutical development may hit the limits for the efficient
treatment of complex disorders.Multicomponent and/or pre-
ventive strategies and the application of mixtures of natural
products might overcome current limitations and improve
the efficacy/toxicity balance [8].
Plants provide a natural resource for treating diverse com-
plex disorders [9]. Extracts from edible biomaterials have be-
come a major focus of nutritional research to develop func-
tional food and nutraceuticals with proven health benefits
and good safety profiles [10]. Here, we report on the benefial
effects of a safe ethanolic extract of lemon balm (Melissa offic-
inalis) leaves on treating hyperglycemia and dyslipidemia in
insulin-resistant high-fat diet-fed mice (where HFD is, high-
fat diet).
Initially, we analyzed binding of PPARs by the ingredi-
ents of a standardized hydroethanolic lemon balm extract
(LBE) [11, 12] using a competitive binding assay. Titration of
the PPAR ligand-binding domain with LBE revealed an over-
all binding affinity constant of 0.6, 0.4, and 1.2 g/mL for
PPAR-, -/, and -, respectively (Fig. 1A–C and Table 1).
In transcriptional reporter gene assays, LBE showed effective
concentrations (EC50) of 46, 882, and 82 g/mL for PPAR-,
-/, and -, respectively, with a maximal potency of 50, 32,
and 12% compared to known full PPAR agonists (Supporting
Information Fig. 1 and Table 1). These results suggest that
LBE comprises pan-PPAR agonists that may regulate PPAR-
directed gene expression inmetabolically relevant target cells.
We therefore tested the ability of LBE to induce PPAR-
regulated gene expression in primary human adipocytes.
LBE-treated cells showed increased expression of exemplary
target genes of the three PPAR subtypes such as the fatty acid
binding protein 4 (FABP4), the fatty acid transport protein
4, the CD36 molecule, the pyruvate dehydrogenase kinase 4
(PDK4), the liver X receptor alpha (LXR- or NR1H3), or the
lipogenic stearoyl-CoA desaturase (Fig. 1D). FABP4 expres-
sion is a marker of adipogenesis and lipid accumulation [13],
and fatty acid transport protein 4 as well as CD36 mediate
fatty acid transport into the adipocytes. PDK4 regulates
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Table 1. PPAR binding and activation data of LBE and reference
compounds
LBE GW7647 GW0742 RGZ
PPAR-
Ki (g/mL or nM) 0.6 13 n.d. n.d.
EC50 (g/mL or nM) 46 0.2 n.d. n.d.
Efficacy (%) 50 100 n.d. n.d.
PPAR-/
Ki (g/mL or nM) 0.4 n.d. 3 n.d.
EC50 (g/mL or nM) 882 n.d. 0.2 n.d.
Efficacy (%) 32 n.d. 100 n.d.
PPAR-
Ki (g/mL or nM) 1.2 n.d. n.d. 17
EC50 (g/mL or nM) 82 n.d. n.d. 4
Efficacy (%) 12 n.d. n.d. 100
LBE data are presented in g/mL, GW7647, GW0742, and RGZ
data are given in nM. LBE, lemon balm extract (g/mL); RGZ,
rosiglitazone (nM); n.d. not determined.
the switch between glucose and fatty acid metabolism, and
increased PDK4 expression indicates intensified entry of
fatty acid oxidation-derived acetyl-CoA into the tricarboxylic
acid cycle. LXR- is a nuclear transcription factor that has
important roles in the regulation of antiinflammatory gene
expression. Of note, the increase in FABP4 expression was
sevenfold lower with LBE than with the anti-diabetes drug
and PPAR- agonist rosiglitazone (RGZ) (Fig. 1D), indicating
lower induction of adipocyte differentiation a process that
might be associated with increased adiposity and body weight
gain in vivo. Knockdown of all three PPAR subtypes in these
cells by small interfering RNA mediated RNA interference
(Supporting Information Fig. 2) led to significant reduction
of the LBE-induced expression of PPAR target genes,
including the cGMP-inhibited phosphodiesterase 3B, the
angiopoietin-like 4 and the stearoyl-CoA desaturase gene
(Fig. 1E). These results indicate LBE-driven modulation
of PPAR activity in primary human adipocytes. Residual
gene expression and physiological activity may have been
maintained by low amounts of PPARs that can synergistically
complement the function of each other, other potentially
compensating nuclear receptors that could also interact with
the ingredients of LBE such as the LXRs [14, 15], or other
off-targets.
We then investigated the effects of LBE in an established
mousemodel ofmild insulin resistance [16].We first induced
insulin resistance and dyslipidemia in C57BL/6mice by feed-
ing a HFD for 18 weeks, and then treated these obese mice
for 6 weeks with 200 mg/kg/day LBE, 4 mg/kg/day RGZ or
vehicle via drinking water. LBE-treatment had no significant
effect on food intake or body weight gain compared to un-
treated mice (Supporting Information Fig. 3). After 2 weeks
of treatment LBE-treated mice revealed significantly reduced
concentrations of fasting blood glucose (14% decrease ver-
sus vehicle, p = 0.001) equally to the potent antidiabetic drug
RGZ (Fig. 2A), whereas LBE showed no significant effects
on fasting plasma insulin levels (Fig. 2B). Combining both
parameters by application of the homeostatis model assess-
ment of insulin resistance, LBE significantly decreased the
HFD-induced insulin resistance by 35% (p = 0.03, Fig. 2C),
approximately half as potent than RGZ (71% decrease,
Fig. 2C). These results indicate strong antidiabetic effects
of LBEs in HFD-fed mice.
Moreover, LBE efficiently reduced the HFD-provoked rise
in fasting plasma concentrations of nonesterified fatty acids
by 59% (p = 0.0006, Fig. 2D) and further potently de-
creased the plasma triacylglycerol gain by 66% (p = 0.00006,
Fig. 2E), even better than RGZ. Strikingly, in contrast to RGZ,
which selectively activates the PPAR- subtype, LBE-fedmice
showed reduced plasma levels of LDL/VLDL cholesterol (32%
decrease, p = 0.006, Fig. 2F), and a slight decrease in to-
tal plasma cholesterol (8% decrease, p = 0.2, Fig. 2F). LBE
treatment led to an increase of the HDL/LDL ratio of 56%
(p = 0.0008; Fig. 2F), whereas RGZ showed no effect. These
data suggest that HFD-induced dyslipidemia can potently be
improved with LBE.
Lemon balm (M. officinalis) is a popular herb of the Lami-
aceae family which is used in tea and food preparations, cos-
metics, and phytomedicals. It has a long tradition as sedative,
spasmolytic, hypotensive, and antimicrobial phytopharma-
ceutical in various cultures [17]. There are to our knowledge
so far no indications for the here-described molecular mech-
anism of PPAR activation and the usage of ethanolic balm
extracts as efficient antidiabetics or antihyperlipidemics [18].
Essential oil prepared from the leaves of lemon balm
was shown to have general antioxidative properties and con-
sequently reduced plasma glucose and triacylglycerols in
monogenic-diabetic db/db mice. In addition, balm oil im-
proved dyslipidemia in apolipoprotein E2 transgenic mice
through sterol regulatory element-binding protein dependent
mechanisms [19]. Aqueous Melissa extracts further showed
hepatoprotective effects in hyperlipidemic rats [20].
Due to their property as nutritional sensors nuclear recep-
tors such as thePPARs are interesting targets for dietary inter-
vention. The present study demonstrated that our ethanolic
LBE contains ligands for all three PPAR subtypes (Ki values
ranging from 0.4 to 1.2 g/mL), indicating that the complex
extract comprises many active ingredients that may address
multiple other targets relevant for the metabolic syndrome.
LBEs contain a large amount of phytochemicals, including
phenolic acids (rosmarinic acid, coumaric acid, caffeic acid
and derivatives, protocatechuic acid, ferulic acid, chlorogenic
acid), flavonoids (quercetin, luteolin, apigenin, and their glu-
cosides), sesquiterpenes (-caryophyllene and germacrene),
monoterpenes (-pinene), and triterpenes [12, 17, 18, 21].
Many of these small molecules have been identified as PPAR
ligands, including rosmarinic acid, apigenin, quercetin, and
luteolin [22].
To further characterise the LBE we subfractionated the ex-
tract and observed in all ten subfractions PPAR--binding
constituents (Ki = 0.3 to 7.5 g/mL, Supplementary In-
formation Fig. 4A), whereas the Ki for the full LBE was
1.2 g/mL. Noteworthy, the binding affinity correlated well
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Figure 2. Antidiabetic and antihyperlipidemic effects of LBE in insulin-resistent diet-induced obese mice. (A) Fasting blood glucose of
untreated HFD-fed mice or mice treated for 2 weeks with RGZ or LBE. (B) Fasting plasma insulin after 2 weeks of treatment. (C) Effect of
treatment for 2 weeks on insulin resistance determined by homeostatis model assessment of insulin resistance (HOMA-IR). (D) Fasting
nonesterified fatty acids after 6 weeks of treatment. (E) Fasting plasma triacylglycerol after 6 weeks of treatment. (F) Fasting plasma total,
HDL, and LDL/VLDL cholesterol, and HDL/LDL ratio in diet-induced obese mice after 6 weeks of treatment. Data are expressed as mean
± SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001, versus vehicle-treated HFD-fed mice. LFD, low-fat diet; HFD, high-fat diet; VEH, vehicle (n =
13–14); RGZ, rosiglitazone (n = 8–14); LBE, lemon balm extract (n = 13–14).
with the hydrophobicity of the subfraction, confirming the
well-known preference of PPAR- for hydrophobic ligands.
However, PPAR-controlled gene expression in the adipocytes
showed lower activation for the stronger PPAR-binding frac-
tions, suggesting counteracting effects of hydrophobicity of
some molecules in the cellular context (Supplementary In-
formation Fig. 4B). These data suggest that optimizing the
extract composition for binding affinity or reporter gene ef-
fective concentrationswould be inefficient for identifiying the
antidiabetic and hypolipidemic constituents in the LBE. Note-
worthy, transcriptional activation of the subfractions was very
diverse for different genes. For example, we observed similar
expression of adiponectin in contrast to varying effects on
NR1H3. These data indicate complex, in part unpredictable
effects on cellular gene regulation due to the so far only partly
understood concerted actions of various transcriptional reg-
ulators.
Consequently, it seems useless to search for few spe-
cific PPAR-modulating ligands or fractions in the whole
extract, whereas the synergistic or additive effects of many
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compounds of the LBE such as (poly)phenols may mediate
the observed activation of PPARs. These effects may have
resulted in the observed improved physiology of insulin-
resistant obese mice treated with the LBE mixture, which
would have been lost, at least in part, by breaking the mixture
down to few single compounds.
The holistic phytomedical poly-drug/poly-target concept
may add fruitful approaches for developing functional food
or nutraceuticals for preventing and treating multifactorial
metabolic diseases [23]. Notably, this approach may over-
come the mentioned problems with undesirable side effects
of strong synthetic PPAR agonists. Moreover, many plant ex-
tracts such as the LBE presented here showed good safety
profiles in humans.
The reasonable concentration of LBE applied in this study
holds promise for application in humans to prevent and coun-
teract polyetiological age-associated metabolic diseases such
as type 2 diabetes and related disorders.
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